AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare giants are navigating a landscape of patent expirations and regulatory shifts. Deciding between AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) requires weighing aggressive growth against diversified stability in a changing market.

AbbVie focuses on high-growth areas such as immunology and neuroscience, seeking to offset revenue losses from older blockbuster drugs. Johnson & Johnson remains a titan of diversification, balancing its innovative medicine segment with a large medical technology business. Investors often compare them because both offer reliable dividends and significant scale.

The case for AbbVie

AbbVie operates as a global biopharmaceutical player focusing on immunology, oncology, neuroscience, and aesthetics. Its distribution is highly concentrated among a few wholesale distributors, such as McKesson Corp (NYSE:MCK) and Cardinal Health (NYSE:CAH), which account for nearly all U.S. sales. Customer concentration like this adds a layer of risk to the business, though the company is actively expanding its research through a multi-year AI partnership.

In FY 2025, revenue reached about $61.2 billion, which is an increase of approximately 9% compared to the prior year. The company reported net income of roughly $4.2 billion for the same period. This resulted in a net margin of close to 7%, which reflects the current costs of diversifying its drug pipeline.

As of its December 2025 balance sheet, the debt-to-equity ratio was negative 21.1x, which means total liabilities exceed shareholder equity. The current ratio, which measures the ability to pay short-term debts with liquid assets, was approximately 0.7x while free cash flow reached about $17.8 billion. This liquidity is vital for maintaining its position among healthcare stocks.

The case for Johnson & Johnson

Johnson & Johnson operates through two primary segments, Innovative Medicine and MedTech, providing a diverse revenue stream across oncology, immunology, and neuroscience. The company is currently separating its Orthopedics business to sharpen its focus on higher-growth medical areas over the next two years. It distributes products globally through various hospitals, wholesalers, and retailers, ensuring its treatments reach patients in virtually every country.

In FY 2025, revenue reached about $94.2 billion, reflecting growth of roughly 6% over the previous year. The company posted net income of approximately $26.8 billion, which is a significant increase from the $14.1 billion reported in the previous year. This performance led to a strong net margin of nearly 29%.

As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of about 0.6x, indicating its total debt is well below its total equity. The current ratio stood at roughly 1.0x, suggesting the company has sufficient short-term assets to cover its immediate liabilities. It also generated nearly $19.7 billion in free cash flow, giving it ample room to invest in new pharmaceutical development.

Risk profile comparison

AbbVie faces significant pressure from the loss of patent exclusivity, which allows generic manufacturers to enter the market. The company also deals with high revenue concentration, as two drugs account for roughly 42% of total net revenues. Additionally, legislative changes like the Inflation Reduction Act create pricing pressures and government-set negotiations for several of its major products, while pipeline failures remain a constant risk.

Johnson & Johnson is managing substantial legal risks related to ongoing litigation involving its talc-based body powders. These claims could result in large financial settlements that impact the company's long-term cash reserves. Furthermore, the company faces regulatory challenges from healthcare reforms that affect pricing and the complex costs associated with the planned separation of its Orthopedics business.

Valuation comparison

Johnson & Johnson trades at a higher premium relative to Forward P/E future earnings estimates, while AbbVie is cheaper based on P/S ratio sales over the past twelve months.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

AbbVie is buying itself growth with its recent buy of Apogee Therapeutics. Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.

Johnson & Johnson is an overlooked behemoth compared to faster growers in the biotech sector. The business has 28 products and platforms that generate more than $1 billion in annual revenue. Its pharmaceuticals arm, Innovative Medicine, has had two FDA approvals this year and has two more approved drug product launches this year in the E.U. and U.S. The Innovative Medicine division is 65% of JNJ's annual revenue and appears to have a robust pipeline beyond those pending products. MedTech, its other arm, sells a wide range of healthcare products, including wound care, surgical instruments and implants, hip and knee replacements, and spinal implants. The recent buy of Atraverse Medical bolsters that business. Revenue for JNJ is expected to rise to $101 billion in the current fiscal year.

Both of these healthcare giants should be viewed through the prism of valuation right now when deciding between them. Abbvie is more affordable with a forward P/E ratio. It also appears that AbbVie has the greater upside, with a pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) to treat schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends Johnson & Johnson and McKesson. The Motley Fool has a disclosure policy.